Search Results - "Yakkala, Prasanna Anjaneyulu"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Rh(III)-Catalyzed [3 + 2] Annulation via C–H Activation: Direct Access to Trifluoromethyl-Substituted Indenamines and Aminoindanes by Chaudhary, Bharatkumar, Auti, Prashant, Shinde, Suchita Dattatray, Yakkala, Prasanna Anjaneyulu, Giri, Deepesh, Sharma, Satyasheel

    Published in Organic letters (19-04-2019)
    “…The rhodium­(III)-catalyzed direct C–H addition and annulation of benzimidates and aldimines with β-(trifluoromethyl)-α,β-unsaturated ketones is described…”
    Get full text
    Journal Article
  2. 2

    Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents by Yakkala, Prasanna Anjaneyulu, Penumallu, Naveen Reddy, Shafi, Syed, Kamal, Ahmed

    Published in Pharmaceuticals (Basel, Switzerland) (01-10-2023)
    “…Topoisomerases are very important enzymes that regulate DNA topology and are vital for biological actions like DNA replication, transcription, and repair. The…”
    Get full text
    Journal Article
  3. 3

    Multicomponent Domino Reaction for Concise Access to 2‑Amino-Substituted 1,3,4 Oxadiazoles via Smiles Rearrangement by Yakkala, Prasanna Anjaneyulu, Khan, Imran A., Dannarm, Srinivas Reddy, Aboti, Jyoti, Sonti, Rajesh, Shafi, Syed, Kamal, Ahmed

    Published in Journal of organic chemistry (01-09-2023)
    “…A multicomponent domino reaction has been developed for the preparation of N-substituted 2-amino-1,3,4-oxadiazoles directly from various hydrazides (32…”
    Get full text
    Journal Article
  4. 4

    Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design by Haider, Kashif, Sharma, Anku, Yar, M Shahar, Yakkala, Prasanna Anjaneyulu, Shafi, Syed, Kamal, Ahmed

    Published in Expert opinion on drug discovery (04-03-2022)
    “…Hyperactivated RAS signaling is reported in 13% of all human cancers, in which ~80% resulted due to KRAS mutations alone. Direct inhibition of KRAS is an…”
    Get more information
    Journal Article
  5. 5

    Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents by Samoon, Rabiya, Sau, Shashikanta, Roy, Arnab, Parida, Kishan Kumar, Sharma, Kalicharan, Yakkala, Prasanna Anjaneyulu, Dewangan, Rikeshwer Prasad, Abdin, Malik Zainul, Kalia, Nitin Pal, Shafi, Syed

    Published in ACS infectious diseases (13-09-2024)
    “…Benzothiazole-bearing compounds have emerged as potential noncovalent DprE1 (decaprenylphosphoryl-β-d-ribose-2′-epimerase) inhibitors active against…”
    Get full text
    Journal Article
  6. 6

    Design and Synthesis of Michael Acceptor‐Based Peptidyl β‐Nitrostyrenes as 3CLpro Inhibitors of SARS‐CoV‐2 by Sharma, Sweta, Yakkala, Prasanna Anjaneyulu, Aboti, Jyoti, Latief, Insha, Ansari, Mairaj Ahmed, Khan, Wajihul Hasan, Shafi, Syed

    Published in ChemistrySelect (Weinheim) (26-06-2023)
    “…Severe Acute Respiratory Syndrome coronavirus 2 main protease was found to be one of the most attractive anti‐viral targets for the development of new chemical…”
    Get full text
    Journal Article
  7. 7

    5‐Arylidene‐2,4‐thiazolidinediones as Cysteine Protease Inhibitors against Leishmania Donovani by Sharma, Sweta, Anjaneyulu Yakkala, Prasanna, Beg, Mirza A., Tanwar, Supriya, Latief, Insha, Khan, Arif, Sharma, Kalicharan, ur Rehman, Sayeed, Selvapandiyan, Angamuthu, Shafi, Syed

    Published in ChemistrySelect (Weinheim) (04-08-2023)
    “…A series of 5‐arylidene‐2,4‐thiazolidinediones were synthesized using Knoevenagel condensation and evaluated for their anti‐leishmanial activity against L…”
    Get full text
    Journal Article